PAPZIMEOS Revenue Hits $21.6M in Q1, Precigen Projects Cash Flow Break-Even by Year-End
PGEN has more than doubled off its 52-week low of $1.26.
Summary
Precigen reported strong first-quarter 2026 financial results, driven by $21.6 million in net product revenue from its PAPZIMEOS launch. This marks a significant positive shift compared to the company's reported $429.6 million net loss for the full year 2025. The company also reported $56.7 million in cash and projects to reach cash flow break-even by the end of 2026, indicating improved financial health and commercial momentum for its key product. This strong revenue performance and positive financial outlook are material developments that could significantly impact investor confidence and the company's valuation. Investors will be watching for updated durability data for PAPZIMEOS at the upcoming ASCO Annual Meeting and a broader AdenoVerse pipeline update later this year.
At the time of this announcement, PGEN was trading at $4.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.26 to $5.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.